DEA Just Classified 3 Kratom-Related Compounds as Schedule I — Here's What's Actually Banned and What Isn't

This article summarizes federal regulatory action for informational purposes and is not medical or legal advice. Anyone with questions about a specific product's legal status should consult their state's current regulations, which vary independently of this federal action.

Key Takeaways

The Drug Enforcement Administration, part of the U.S. Department of Justice, has classified three semisynthetic opioid-like compounds related to kratom as Schedule I substances on an emergency basis, according to an announcement released August 25, 2026.
The emergency scheduling lasts two years and places these compounds in the same federal category as heroin, LSD, and cannabis — substances the government defines as having "no currently accepted medical use and a high potential for abuse."
Two of the three newly scheduled compounds are currently sold in consumer products such as powders, chewable tablets, and liquid shots at gas stations, smoke shops, and convenience stores.
Natural, unprocessed kratom itself is not covered by this specific action — the ban targets concentrated semisynthetic derivatives, not the raw plant material long sold as traditional kratom.
Kratom's legal status already varies significantly by state: natural kratom is regulated in at least 22 states and outright banned in eight, including Alabama, Connecticut, Ohio, and Vermont, independent of this federal action.

What was actually banned, and what wasn't

It's worth being precise about the scope of this action, because it's narrower than "kratom is now illegal" — a characterization that would overstate what actually happened. The DEA's emergency scheduling applies specifically to three semisynthetic opioid-like compounds derived from or related to kratom's natural alkaloids, not to raw, unprocessed kratom leaf or powder itself. Two of the three compounds are currently sold as standalone consumer products in their own right — including 7-hydroxymitragynine, or "7-OH," a concentrated derivative that has become increasingly common in gas-station and smoke-shop products marketed separately from traditional kratom.

U.S. Attorney General Todd Blanche framed the action as preemptive, saying in the announcement that "the Justice Department is acting before these dangerous compounds become a broader threat" — language that signals the DEA views these concentrated derivatives as a distinct, escalating concern compared to the traditional plant product that's been sold in the U.S. for years.

Why this targets 7-OH specifically

The regulatory concern centers on a specific pharmacological distinction that federal health agencies have been building a case around for months. The National Institute on Drug Abuse (NIDA) has said that 7-OH can cause opioid-like respiratory depression — the same dangerous breathing suppression associated with opioid overdoses — that can be reversed with naloxone, the standard opioid-overdose reversal medication. Critically, NIDA has said mitragynine and natural kratom leaf have not shown that same respiratory-depression effect, a distinction that helps explain why regulators have moved to separate concentrated 7-OH products from the natural plant material in their scheduling approach, rather than treating all kratom-related substances identically.

The Department of Health and Human Services separately told the DEA that synthetic 7-OH and the related compounds have no accepted medical use and carry a high potential for abuse — the specific two-part legal standard that Schedule I classification requires under the Controlled Substances Act.

How we got here: a longer regulatory buildup

This emergency action didn't emerge without warning. The DEA had signaled its intent to control 7-OH as far back as July 2026, when it announced plans to place the compound under emergency Schedule I control, with that earlier order not taking effect before August 5. The FDA had also previously stated its own position that kratom qualifies as an opioid and discouraged its use, adding federal agency weight to state-level actions that had already been building for years.

Ahead of this federal action, individual states had already begun restricting 7-OH specifically — Florida, Ohio, Kentucky, and California had each moved to classify semisynthetic 7-OH as a Schedule I substance or otherwise restrict it at the state level, meaning the federal action follows a pattern several states had already established rather than being the first regulatory move against these compounds.

Congress has also been separately considering legislation on this exact question: Rep. Gus Bilirakis (R-Fla.) introduced the END 7-OH Act (H.R. 8000) in March 2026, which would permanently schedule synthetic 7-OH at the federal level while explicitly excluding 7-OH naturally occurring within kratom leaf itself — an approach designed to draw a clear legal line between concentrated manufactured derivatives and the traditional plant product, a distinction the current emergency DEA action broadly mirrors, though through executive rather than legislative action.

Not everyone agrees with how this is being done

The scheduling approach has drawn direct criticism over process, not just substance. Sens. Ron Wyden, Cory Booker, and Kirsten Gillibrand sent a letter to the DEA's acting administrator expressing concern that the agency's action moved forward without what they characterized as a sufficiently robust process for stakeholder input, and specifically asked the agency to delay its decision and allow more time for public comment on the medical, public safety, and scientific considerations involved. That objection reflects a broader, recurring tension in emergency drug scheduling: the DEA's emergency authority under the Controlled Substances Act is specifically designed to allow faster action than the standard rulemaking process, precisely by bypassing the extended public comment period that a normal scheduling decision would otherwise require — a tradeoff between speed and deliberation that critics argue works against affected consumers and researchers.

What this means if you use kratom products

Check specifically which product you have — natural kratom leaf or powder is not covered by this federal emergency action, but concentrated 7-OH products and the other two newly scheduled compounds are now federally illegal to possess or sell.
Know that your state's rules may already be stricter than federal law was until now — if you live in one of the eight states that had already banned kratom outright, or one of the 22 states regulating it, this federal action doesn't change what was already true for you locally.
Understand this is a two-year emergency measure, not necessarily permanent — emergency Schedule I scheduling under the Controlled Substances Act is time-limited, and a permanent classification would require the DEA to complete additional rulemaking steps, or Congress could act separately through legislation like the pending END 7-OH Act.
Watch for retailer-level changes even in states where natural kratom remains legal — because two of the three newly scheduled compounds were sold as standalone consumer products at convenience stores and smoke shops, expect those specific products to disappear from shelves nationally even where broader kratom sales continue.

Frequently Asked Questions

Is kratom illegal now? Not entirely. This DEA action places three specific semisynthetic compounds — including concentrated 7-OH products — in the Schedule I category. Natural, unprocessed kratom leaf and powder are not covered by this specific federal action, though many states independently regulate or ban natural kratom as well.

What is 7-OH, and how is it different from regular kratom? 7-hydroxymitragynine (7-OH) is a concentrated derivative compound that federal health researchers say can cause opioid-like respiratory depression, an effect not observed with natural kratom leaf or its primary alkaloid, mitragynine.

How long does this ban last? The DEA's action is an emergency scheduling that lasts two years under the Controlled Substances Act, rather than a permanent classification.

Is there a difference between state and federal kratom laws? Yes. Kratom's legal status has varied by state independent of federal action — it's regulated in at least 22 states and outright banned in eight, including Alabama, Connecticut, Ohio, and Vermont, regardless of what federal scheduling applies to specific derivative compounds.

Sources & References

CNN, "DEA temporarily makes kratom-related compounds Schedule I substances" (August 31, 2026)
WISN / CNN, "DEA makes kratom-related compounds Schedule I substances on an emergency basis"
Legis1, "DEA Places Kratom Alkaloid Under Emergency Schedule I Control"
Office of Sen. Ron Wyden, "Wyden, Booker, Gillibrand Express Concern about DEA Process to Schedule Kratom"